Promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia.has been published in Nature. This was announced by Bluebird bio (formerly Genetix Pharmaceuticals Inc.) an emerging leader in the development of innovative gene therapies for severe genetic disorders. Thalassemia is a blood disorder that is one of the most frequent inherited diseases.
The patient, who had been transfusion dependent since early childhood, has become transfusion independent for the past 21 months - more than two years after treatment with the LentiGlobin vector. The study also identified a subset of cells with the corrected beta-globin gene that overexpressed a truncated form of a gene called HMGA2. The patient has not experienced any adverse events. The data show that while early on, the HMGA2 clone was a significant portion of the corrected cells, the clone levels had declined at the time the paper was prepared, and further follow up indicates the decline is continuing.
Thalassemia
Thalassemia is an inherited blood disorder passed on through parental genes causing the body to produce abnormal hemoglobin.
"Although based on the first treated patient, we believe these results are impressive and illustrate for the first time the significant potential for treatment of beta hemoglobinopathies using lentiviral beta-globin gene transfer in the context of autologous stem cell transplant," said Philippe Leboulch, M.D., senior author of the study and head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; professor of medicine, University of Paris; and visiting professor, Harvard Medical School. "For beta-thalassemia, we have worked intensely for almost 20 years to design, develop and manufacture LentiGlobin to provide a sustained high level hemoglobin production, resulting in a major clinical benefit. It has been very rewarding to follow this patient as his life has dramatically improved since receiving our treatment."
DNA Finger Printing
DNA fingerprinting is a technique which helps forensic scientists and legal experts solve crimes, identity thefts, legal suits and terrorism cases.
The paper, titled "Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassemia," is available in the online publication of Nature at www.nature.com.
"We believe the human findings in beta-thalassemia, as well as the recently published data in Science on two patients with childhood cerebral adrenoleukodystrophy (CCALD), highlight the significant opportunity for bluebird bio's gene therapy platform to help patients with severe genetic disorders," said Nick Leschly, president and CEO of bluebird bio. "We are committed to building a world-class company in gene therapy led by outstanding people as we move aggressively forward with multiple clinical studies, including our ongoing clinical trials for the development of LentiGlobin for beta-thalassemia and our product for CCALD."
Source: Eurekalert
Thalassemia may Protect Kids from Malaria
In a new study, researchers have found that the blood disease alpha thalassemia may protect kids from malaria.
 Iron Overload In Thalassemia - New Cause DiscoveredAccording to researchers at the NIH, iron overload in patients with thalassemia can be caused due to an overproduction of a protein called GDF15. | Advertisement
|
